Pennsylvania is currently home to 3307 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Early Intervention for Youth At High Risk for Bipolar Disorder
NCT04815239
Recruiting
Investigators will conduct a confirmatory efficacy trial of Interpersonal and Social Rhythm Therapy (IPSRT) delivered via telehealth for offspring of bipolar parents (OBP; age 12-18, n=120) at elevated risk for BP onset via risk calculator score. All participants receive a baseline clinical assessment of psychiatric symptoms and sleep disturbance (via objective and subjective methods), followed by a feedback session. Youth are then randomized to receive 8 sessions of IPSRT or a manualized Health... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
03/21/2025
Locations: Nicole Arnold, Pittsburgh, Pennsylvania
Conditions: Bipolar Disorder
Register for Updates
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
NCT04796337
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: UPMC Presbyterian. UPMC Presbyterian Hospital ( Site 1059), Pittsburgh, Pennsylvania
Conditions: PAH, Pulmonary Arterial Hypertension
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
NCT04157985
Recruiting
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Register for Updates
Transdermal Estrogen in Women with Anorexia Nervosa
NCT03875378
Recruiting
Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.
Gender:
FEMALE
Ages:
Between 19 years and 45 years
Trial Updated:
03/21/2025
Locations: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Conditions: Anorexia Nervosa
Register for Updates
Autonomic Control of the Circulation and VDR
NCT03513770
Recruiting
The study objective of this project is to examine the mechanisms of the venous distension reflex (VDR) in humans. We hypothesize that COX blockade with ketorolac tromethamine, an intravenous NSAID, will attenuate the muscle sympathetic nerve activity (MSNA) response to limb venous distension. To gain further insight into whether the COX byproducts directly stimulate chemically-sensitive afferents, or enable venodilation and indirectly evoke afferent stimulation, we will measure vein size using 3... Read More
Gender:
ALL
Ages:
Between 21 years and 35 years
Trial Updated:
03/21/2025
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Venous Distension Reflex, Blood Pressure
Register for Updates
The Venous Distension Reflex and Orthostatic Hypertension
NCT03496792
Recruiting
This research is being done to find out whether distension of veins in legs will cause a rise in blood pressure (orthostatic hypertension).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Blood Pressure
Register for Updates
Efficacy and Safety of VDPHL01 in Males with AGA
NCT06724614
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
03/20/2025
Locations: Site 08, Broomall, Pennsylvania
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
Multisite Virtual Reality Intervention for Speech Anxiety
NCT06593847
Recruiting
Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: Albright College, Reading, Pennsylvania
Conditions: Public Speaking, Speech Anxiety
Register for Updates
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06533644
Recruiting
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Study of Andecaliximab in Participants with Fibrodysplasia Ossificans Progressiva (FOP)
NCT06508021
Recruiting
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking at several research questions, including: * Safety of andecaliximab in participants with FOP * Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO) * Whether andecalixim... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
03/20/2025
Locations: The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania
Conditions: Fibrodysplasia Ossificans Progressiva
Register for Updates
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948
Recruiting
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Investigational Site # 34, Pittsburgh, Pennsylvania
Conditions: Atopic Dermatitis
Register for Updates